Andy P / Shutterstock.com
London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy.
Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.
Some of the approaches they use—such as big data analysis and virtual organs—could be said to be almost as innovative as the products being developed. But there’s another solution: to use existing technologies in a different way.
Imaging technologies such as positron emission tomography (PET), usually used to show three-dimensional images of cancerous tumours or brain activity, can also show a drug’s interaction with disease targets inside the human body, and play a part in disease function research.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Imanova, imaging biomarkers, PET, GlaxoSmithKline